Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection

Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs CR 8020 (Primary) ; Diridavumab (Primary)
  • Indications Influenza A virus infections
  • Focus Therapeutic Use
  • Sponsors Janssen Vaccines and Prevention
  • Most Recent Events

    • 03 Aug 2017 This trial has been discontinued in Belgium.
    • 03 Mar 2014 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 07 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top